PM

Peter M. Hecht

North America, Massachusetts, United States, Cambridge

Description

Peter Hecht is the Co-Founder and CEO of Cyclerion Therapeutics. He previously worked at Ironwood Pharmaceuticals as a Co-Founder and CEO. P...

Investor Profile

Peter M. Hecht has made 3 investments, with 0 in the past 12 months and 33% as lead.

Stage Focus

  • Post Ipo Equity (67%)
  • Series A (33%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Medical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Peter M. Hecht frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 1
Co-Investments: 1
J. Wood Capital Advisors
North America, California, United States, Santa Rosa
Co-Investments: 1
SP
North America, New York, United States, New York
Co-Investments: 1
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 2
Sanofi Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Venrock
North America, California, United States, Palo Alto
Co-Investments: 1
Invus
North America, New York, United States, New York
Co-Investments: 2
Lincoln Park Capital Fund
North America, Illinois, United States, Chicago
Co-Investments: 1

What are some of recent deals done by Peter M. Hecht?

Tisento Therapeutics

Cambridge, Massachusetts, United States

Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.

Health CareMedicalTherapeutics
Series AJul 31, 2023
Amount Raised: $81,000,000
Cyclerion Therapeutics

Cambridge, Massachusetts, United States

Cyclerion Therapeutics harnesses the potential of soluble guanylate cyclase (sGC) pharmacology.

BiotechnologyPharmaceutical
Post Ipo EquityMay 25, 2023
Amount Raised: $5,000,000
Cyclerion Therapeutics

Cambridge, Massachusetts, United States

Cyclerion Therapeutics harnesses the potential of soluble guanylate cyclase (sGC) pharmacology.

BiotechnologyPharmaceutical
Post Ipo EquityJun 4, 2021
Amount Raised: $18,000,000